During the past decade, CARE-ID conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 2 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CARE-ID" #1 sponsor was "Gilead Sciences" with 2 trials, followed by "Eli Lilly and Company" with 1 trials sponsored, "Graceway Pharmaceuticals, LLC" with 1 trials sponsored, "Koronis Pharmaceuticals." with 1 trials sponsored and "Myrexis Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CARE-ID" #1 collaborator was "AbCellera Biologics Inc." with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator, "Shanghai Junshi Bioscience Co., Ltd." with 1 trials as a collaborator and "Vir Biotechnology, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "CARE-ID" are "HIV Infections" (3 trials), "Acquired Immunodeficiency Syndrome" (1 trials), "COVID-19" (1 trials), "Genital Warts" (1 trials) and "HIV-1 Infection" (1 trials). Many other conditions were trialed in "CARE-ID" in a lesser frequency.

Most popular intervention types in "CARE-ID" are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "2.5% imiquimod cream" (1 trials), "3-4 commercially available antiretroviral drugs" (1 trials), "3.75% imiquimod cream" (1 trials), "Bamlanivimab" (1 trials) and "Bebtelovimab" (1 trials). Other intervention names were less common.

The vast majority of trials in "CARE-ID" are 6 trials for "All" genders.

Currently, there are NaN active trials in "CARE-ID". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in CARE-ID, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in CARE-ID, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".